Strategies for targeting protein therapeutics to selected tissues and cells

Bibliography

• DAUGHERTY AL, MRSNY RJ: Emergingtechnologies that overcome biological barriers for therapeutic protein delivery. Expert Opin. Biol. Ther. (2003) 3(7):1071–1081.
   PubMed Web of Science ®Google Scholar
• •Recent review pointing out other delivery issues for protein therapeutics.
   Google Scholar
• HARIAWALA MD, HOROWITZ JR, ESAKOF D et al.: VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts.Stag. Res. (1996) 63(1):77–82.
   Google Scholar
• SPARANO J: Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin. Oncol (2001) 28(1 Suppl. 3):20–27.
   Google Scholar
• LEONARD JP, SHERMAN ML,FISHER GL et al.: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 90(7):2541–2548.
   Google Scholar
• DE FOST M, AERTS JM, HOLLAK CE: Gaucher disease: from fundamental research to effective therapeutic interventions. Neth. Med. (2003) 61(1):3–8.
   PubMed Web of Science ®Google Scholar
• DAUGHERTY AL, PATAPOFF TW, CLARK RC, SINICROPI DV, MRSNY RJ: Compaction assay: a rapid and simple M vitro method to assess the responsiveness of a biopolymer matrix to enzymatic modification. Biomaterials (1995) 16(7):553–558.
   PubMed Web of Science ®Google Scholar
• MRSNY RJ, DAUGHERTY AL,SHORT SM, WIDMER R, SIEGEL MW, KELLER GA: Distribution of DNA and alginate in purulent cystic fibrosis sputum: implications to pulmonary targeting strategies. Drug Target. (1996) 4(4):233–243.
   PubMed Web of Science ®Google Scholar
• JOHNSON CA, BUTLER SM, KONSTAN MW, BREEN TJ, MORGAN WJ: Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.Pediatr. (1999) 134(6):734–739.
   Google Scholar
• DAUGHERTY AL, MCKEE ML, FITZGERALD DJ, MRSNY RJ: Epithelial application of Pseudomonas aeruginosa exotoxin A results in a selective targeting to cells in the liver, spleen and lymph node. J. Control. Release (2000) 65(1-2):297–302.
   PubMed Web of Science ®Google Scholar
• LU Q, HOPE LW, BRASCH M, REINHARD C, COHEN SN: TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation. Proc. Natl Acad. Sci. USA (2003) 100(3):7626–7631.
   PubMedGoogle Scholar
• SIX I, KUREISHI Y, LUO Z, WALSH K et al.: Aid signaling mediates VEGFNPF vascular permeability in vivo. FEBS Lett. (2002) 532(1-2):67–69.
   PubMed Web of Science ®Google Scholar
• ENNETT A, MOONEY D: Tissue engineering strategies for in vivo neovascularisation. Expert Opin. Biol. Tiler: (2002) 2(8):805–818.
   PubMed Web of Science ®Google Scholar
• MAEDA H: The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul (2001) 41:189–207.
   PubMedGoogle Scholar
• ••Describes the important conceptof tumours having increasedvascular permeability.
   Google Scholar
• JAAFARI MR, FOLD VARI M: Targeting of liposomes to melanoma cells with high levels of ICAM-1 expression through adhesive peptides from immunoglobulin domains.Pharm. Sci. (2002) 91(2):396–404.
   Google Scholar
• DAVIDSEN J, JORGENSEN K, ANDRESEN TL, MOURITSEN OG: Secreted phospholipase A(2) as a newenzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim. Biophys. Acta (2003) 1609(1):95–101.
   PubMed Web of Science ®Google Scholar
• KAO WJ, LIU Y, GUNDLOORI R et al.: Engineering endogenous inflammatory cells as delivery vehicles. Control. Release(2002) 78(1-3):219–233.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, TOMASONI S,REMUZZI G: Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. Kidney Int. Sapp]. (2002) 61\(Suppl. 1):115–119.
   Google Scholar
• HOFLAND HE, MASS ON C, IGINLA S et al.: Folate-targeted gene transfer in vivo. Ma The]: (2002) 5(6):739–744.
   PubMed Web of Science ®Google Scholar
• MANDAL AK, SINHA J, MANDAL S, MUKHOPADHYAY S, DAS N: Targeting of liposomal flavonoid to liver in combating hepatocellular oxidative damage. Drug Deify. (2002) 9(3):181–185.
   Google Scholar
• OPANASOPIT P, HYOUDOU K, NISHIKAWA M, YAMASHITA F, HASHIDA M: Serum mannan binding protein inhibits mannosylated liposome-mediated transfection to macrophages. Biochim. Biophys. Acta (2002) 1570(3):203–209.
   PubMed Web of Science ®Google Scholar
• PONNAPPA BC, ISRAEL Y: Targeting Kupffer cells with antisense oligonucleotides. Front. BioscL (2002) 7:e223–e233.
   PubMed Web of Science ®Google Scholar
• MOREIRA JN, GASPAR R, ALLEN TM: Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochim. Biophys. Acta (2001) 1515(2):167–176.
   PubMed Web of Science ®Google Scholar
• AWASTHI VD, GOINS B, KLIPPER R, PHILLIPS WT: Accumulation of PEG-liposomes in the inflamed colon of rats: potential for therapeutic and diagnostic targeting of inflammatory bowel diseases.Drug Target. (2002) 10(5):419–427.
   PubMed Web of Science ®Google Scholar
• HOOD JD, BEDNARSKI M,FRAUSTO R et al.: Tumor regression by targeted gene delivery to the neovasculature.Science (2002) 296(5577):2404–2407.
   Google Scholar
• SCHRAA AJ, EVERTS M, KOK RJ et al.: Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. Biotechnol Ann. Rev (2002) 8:133–165.
   PubMedGoogle Scholar
• ••Excellent overview of vasculartargeting strategies.
   Google Scholar
• CHANG YS, DI TOMASO E,MCDONALD DM, JONES R, JAIN RK, MUNN LL: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sri. USA (2000) 97(26):14608–14613.
   PubMed Web of Science ®Google Scholar
• BERGERS G, SONG S,MEYER-MORSE N, BERGSLAND E, HANAHAN D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Clin. Invest. (2003) 111(9):1287–1295.
   Google Scholar
• FARBER DL, AHMADZADEH M: Dissecting the complexity of the memory T cell response. Immunol Res. (2002) 25(3):247–259.
   PubMed Web of Science ®Google Scholar
• KANNAGI R: Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Carr. Opin. Smart. Biol. (2002) 12(5):599–608.
   Web of Science ®Google Scholar
• ••Outlines the concept of a cellularaddressing system in the body.
   Google Scholar
• OKAMOTO R, YAJIMA T,YAMAZAKI M et al.: Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat. Med. (2002) 8(9):1011–1017.
   Google Scholar
• MCINTOSH DP, TAN XY, OH P, SCHNITZER JE: Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Natl. Acad. Sri. USA (2002) 99(4):1996–2001.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM: Drug and gene delivery to the brain: the vascular route. Neuron (2002) 36(4):555–558.
   PubMed Web of Science ®Google Scholar
• THOLE M, NOBMANNA S, HUWYLER J, BARTMANN A, FRICKER G: Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J. Drug Target. (2002) 10(4):337–344.
   PubMed Web of Science ®Google Scholar
• GARNETT MC: Targeted drug conjugates: principles and progress. Adv. Drug Deify. Rev. (2001) 53(2):171–216.
   PubMed Web of Science ®Google Scholar
• ARAP W, PASQUALINI R,RUOSLAHTI E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 279(5349):377–380.
   PubMed Web of Science ®Google Scholar
• SHADIDI M, SIOUD M: Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB (2003) 17(2):256–258.
   PubMedGoogle Scholar
• LEACH JK, HINMAN A, O'REAR EA: Investigation of deformability, viscosity, and aggregation of mPEG- modified erythrocytes. Biomed. Sci. Insmum. (2002) 38:333–338.
   PubMedGoogle Scholar
• HAMIDI M, TAJERZADEH H: Carriererythrocytes: an overview. Drug Deify.(2003) 10(1):9–20.
   Google Scholar
• •Outlines opportunities for cell-based drug delivery.
   Google Scholar
• GURISH ME TAO H, ABONIA JP et al.: Intestinal mast cell progenitors require CD49dbeta7 (alpha4beta7 integrin) for tissue-specific homing. J. Exp. Med. (2001) 194(9):1243–1252.
   Google Scholar
• TERAI S, YAMAMOTO N, OMORI K, SAKAIDA I, OKITA K: A new cell therapy using bone marrow cells to repair damaged liver. J. Castroenterol (2002) 37\(Suppl. 14):162–163.
   Google Scholar
• HESS D, MARTIN M, SAKANO S et al.: Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol (2003) 21(4763–770.
   Google Scholar
• BROWN DA, LONDON E: Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. (2000) 275(23):17221–17224.
   PubMed Web of Science ®Google Scholar
• GUMBLETON M, HOLLINS AJ, OMIDI Y, CAMPBELL L, TAYLOR G: Targeting caveolae for vesicular drug transport. Control. Release (2003) 87(1-3):139–151.
   PubMed Web of Science ®Google Scholar
• HUSSEY SL, PETERSON BR: Efficient delivery of streptavidin to mammalian cells: clathrin- mediated endocytosis regulated by a synthetic ligand. Am. Chem. Soc. (2002) 124(22):6265–6273.
   PubMed Web of Science ®Google Scholar
• HAAS A: Reprogramming the phagocytic pathway-intracellular pathogens and their vacuoles (review). MM. Mem& Biol. (1998) 15(3):103–121.
   Web of Science ®Google Scholar
• DUNCAN R, GAC-BRETON S,KEANE R et al: Polymer-drug conjugates,PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release (2001) 74(1-3):135–146.
   PubMed Web of Science ®Google Scholar
• ASOKAN A, CHO MJ: Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. J. Pharm. (2002) 91(0903–913.
   PubMed Web of Science ®Google Scholar
• KELLER G-A, LI W, MRSNY RJ: Targeting macromolecular therapeutics to specific cell organelles. In: Controlled Drug Delivery,: Designing Technologies for the Future, Park K, Mrsny RJ (Eds), American Chemical Society, Washington DC (2000):168–183.
   Google Scholar
• GOLEMIS EA, OCHS MEPUGACHEVA EN: Signal transduction driving technology driving signaltransduction: factors in the design oftargeted therapies.Biochem. Sapp].(2001) Suppl. 37:42–52.
   Google Scholar
• KLUMPP DJ, FORRESTAL SG,KARR JE, MUDGE CS, ANDERSON BE, SCHAEFFER AJ: Epithelial differentiation promotes the adherence of type 1-piliated Escherichia coil to human vaginal cells. J. Infect. Dis. (2002) 186(141631–1638.
   Google Scholar
• HUGHES MD, HUSSAIN M, NAWAZ Q, SAYYED P, AKHTAR S: The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov. Today (2001) 6(6):303–315.
   PubMed Web of Science ®Google Scholar
• XI S, GRANDIS JR: Gene therapy for the treatment of oral squamous cell carcinoma. J. Dent. Res. (2003) 82(1):11–16.
   PubMed Web of Science ®Google Scholar
• MURATOVSKA A,LIGHTOWLERS RN, TAYLOR RW, WILCE JA, MURPHY MP: Targeting large molecules to mitochondria. Adv. Drug Deify. Rev (2001) 49(1-2):189–198.
   PubMed Web of Science ®Google Scholar
• ALTO N, CARLISLE MICHEL JJ, DODGE KL, LANGEBERG LK, SCOTT JD: Intracellular targeting of protein kinases and phosphatases. Diabetes (2002) 51\(Suppl. 3):S385–S388.
   Google Scholar
• ••Excellent discussion of potentialtherapeutic targets for intracellular protein drug delivery.
   Google Scholar
• WADHWA M, SKOG AL, BIRD C et al.: Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy withGM-CSF. Gin. Cancer Res. (1999) 5(6):1353–1361.
   Web of Science ®Google Scholar
• MURTHY N, CAMPBELL J, FAUSTO N, HOFFMAN AS, STAYTON PS: Design and synthesis of pH-responsive polymericExpert Op/n. Biol. Ther. (2004) 4(1) carriers that target uptake and enhance the intracellular delivery of oligonucleotides. J. Control. Release (2003) 89(3):365–374.
   Google Scholar
• AHMED A, THOMPSON J, EMILIUSEN L et al.: A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization.Nat. Biotechnol (2003) 21(7):771–777.
   Google Scholar
• YAMADA T, IWASAKI Y, TADA H et al.: Nanoparticles for the delivery of genes and drugs to human hepatocytes.Nat. Biotechnol (2003) 21(8):885–890.
   Google Scholar
• BARANOWSKI E, RUIZ-JARABO CM, DOMINGO E: Evolution of cell recognition by viruses. Science (2001) 292(5519):1102–1105.
   PubMed Web of Science ®Google Scholar
• WANG X, HUONG SM, CHIU ML, RAAB-TRAUB N, HUANG ES: Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature (2003) 424(6947):456–461.
   PubMed Web of Science ®Google Scholar
• MOSTOV K, SU T, TER BEEST M: Polarized epithelial membrane traffic: conservation and plasticity. Nat. Cell. Biol. (2003) 5(4):287–293.
   PubMed Web of Science ®Google Scholar
• VAN IJZENDOORN SC, MATER 0, VAN DER WOUDEN JM,HOEKSTRA D: The subapical compartment and its role in intracellular trafficking and cell polarity. j. Cell. Physiol (2000) 184(2):151–160.
   PubMed Web of Science ®Google Scholar
• ACKERMAN AL, CRESSWELL P: Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. J. Immunol. (2003) 170(8):4178–4188.
   PubMed Web of Science ®Google Scholar
• FEHRENBACHER KL, BOLDOGH IR, PON LA: Taking the A-train: actin-based force generators and organelle targeting. Trends Cell Biol. (2003) 13(9):472–477.
   PubMed Web of Science ®Google Scholar
• BROKX RD, BISLAND SK, GARIEPY J: Designing peptide-based scaffolds as drug delivery vehicles. J. Control. Release (2002) 78(1-3):115–123.
   PubMed Web of Science ®Google Scholar
• ALLAN VJ, THOMPSON HM, MCNIVEN MA: Motoring around the Golgi. Nat. Cell. Biol. (2002) 4(10):E236–E242.
   PubMed Web of Science ®Google Scholar
• CHRISTOPHE D,CHRISTOPHE-HOBERTUS C, PICHON B: Nuclear targeting of proteins: how many different signals? Cell. Signal. (2000) 12(5):337–341.
   PubMed Web of Science ®Google Scholar
• MEACOCK SL, GREENFIELD JJ, HIGH S: Protein targeting and translocation at the endoplasmic reticulum membrane-through the eye of a needle? Essays Biochem. (2000) 36:1–13.
   Google Scholar
• DUNCAN R: The dawning era of polymer therapeutics. Nat. Rev Drug Discov. (2003) 2(5):347–360.
   PubMed Web of Science ®Google Scholar
• SAHOO SK, PANYAM J, PRABHA S, LABHASET WAR V: Residual polyvinyl alcohol associated with poly (D,L-lactide-co- glycolide) nanoparticles affects their physical properties and cellular uptake.Control. Release (2002) 82(1):105–114.
   Google Scholar
• SCHWARZE SR, HRUSKA KA, DOWDY SF: Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. (2000) 10(7):290–295.
   Google Scholar
• GRATTON JP, YU J, GRIFFITH JVV et al: Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat. Med. (2003) 9(3):357–362.
   PubMed Web of Science ®Google Scholar
• ••Method of intracellular delivery usingmembrane-permeable peptides.
   Google Scholar
• MANDAL M, LEE KD: Listeriolysin 0-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim. Biophys. Acta (2002) 1563(1-2):7–17.
   PubMed Web of Science ®Google Scholar
• ELLIOTT G, O'HARE P: Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell (1997) 88(2):223–233.
   PubMed Web of Science ®Google Scholar
• MASTROBATTISTA E, STORM G, VAN BLOOIS L et al.: Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim. Biophys. Acta (1999) 1419(2):353–363.
   Google Scholar
• COSTIN GE, TRIF M, NICHITA N, DWEK RA, PETRESCU SM: pH-sensitive liposomes are efficient carriers for endoplasmic reticulum- targeted drugs in mouse melanoma cells. Biochem. Biophys. Res. Commun. (2002) 293(3):918–923.
   PubMed Web of Science ®Google Scholar
• HARRIS JM, MARTIN NE, MODI M: Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. (2001) 40(7):539–551.
   PubMed Web of Science ®Google Scholar
• SUGINOSHITA Y, TABATA Y, MATSUMURA T et al.: Liver targeting of human interferon-beta with pullulan basedon metal coordination. J. Control. Release (2002) 83(1):75–88.
   PubMed Web of Science ®Google Scholar
• XIANG J, QI Y, COOK D, MOYANA T: Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells. Hum. Antibodies Hybridomas (1996) 7(1):2–10.
   PubMedGoogle Scholar
• BOWEN S, TARE N, INOUE T et al.: Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp. Hematol (1999) 27(3):425–432.
   PubMed Web of Science ®Google Scholar
• FRANKEL AE, POWELL BL, HALL PD, CASE LD, KREITMAN RJ: Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin. Cancer Res. (2002) 8(5):1004–1013.
   PubMed Web of Science ®Google Scholar
• CARNEMOLLA B, BORSI L, BALZA E et al.: Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 99(5):1659–1665.
   PubMed Web of Science ®Google Scholar
• OKAZAKI K, NAKASE H,WATANABE N, TABATA Y, IKADA Y, CHIBA T: Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis.Gastroentera (2002) 37\(Suppl. 14):44–52.
   Google Scholar
• HALIN C, RONDINI S, NILSSON F et al.: Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol (2002) 20(3):264–269.
   PubMed Web of Science ®Google Scholar
• MELANI C, FIGINI M, NICOSIA D et al.: Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. (1998) 58(18):4146–4154.
   PubMed Web of Science ®Google Scholar
• CARVER LA, SCHNITZER JE: Caveolae: mining little caves for new cancer targets. Nat. Rev Cancer (2003) 3(8):571–581.Affiliation
   Google Scholar